IMVT
Income statement / Annual
Last year (2024), Immunovant, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Immunovant, Inc.'s net income was -$259.34 M.
See Immunovant, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$231,000.00
|
$1.32 M
|
$1.23 M
|
$998,000.00
|
$21,000.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$231,000.00
|
-$1.32 M
|
-$1.23 M
|
-$998,000.00
|
-$21,000.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$212.93 M
|
$160.26 M
|
$101.81 M
|
$68.60 M
|
$47.93 M
|
$25.73 M
|
$135.26 M
|
| General & Administrative Expenses |
$57.28 M
|
$48.02 M
|
$54.23 M
|
$39.51 M
|
$18.15 M
|
$2.69 M
|
$1.48 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.69 M
|
$0.00
|
| Selling, General & Administrative Expenses |
$57.28 M
|
$48.02 M
|
$54.23 M
|
$39.51 M
|
$18.15 M
|
$448.00
|
$1.48 M
|
| Other Expenses |
$12.50 M
|
-$253,000.00
|
-$781,000.00
|
$328,000.00
|
$412,000.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$282.71 M
|
$208.28 M
|
$156.03 M
|
$108.12 M
|
$66.08 M
|
$448.00
|
$136.74 M
|
| Cost And Expenses |
$282.71 M
|
$208.28 M
|
$156.03 M
|
$108.12 M
|
$66.08 M
|
$448.00
|
$136.74 M
|
| Interest Income |
$24.95 M
|
$7.58 M
|
$0.00
|
$0.00
|
$625.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$12.48 M
|
$655,000.00
|
$0.00
|
$625,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$231,000.00
|
$1.32 M
|
$1.23 M
|
$998,000.00
|
$21,000.00
|
$10,000.00
|
$136.74 M
|
| EBITDA |
-$269.98 M |
-$209.63 M |
-$155.58 M |
-$106.79 M |
-$65.65 M |
-$28.42 M |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$23.94 M
|
-$2.68 M
|
-$781,000.00
|
$328,000.00
|
-$2.51 M
|
$0.00
|
$116.00
|
| Income Before Tax |
-$258.77 M
|
-$210.95 M
|
-$156.81 M
|
-$107.79 M
|
-$66.29 M
|
-$448.00
|
-$136.74 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$567,000.00
|
$9,000.00
|
-$84,000.00
|
-$358,000.00
|
$97,000.00
|
$19,000.00
|
$0.00
|
| Net Income |
-$259.34 M
|
-$210.96 M
|
-$156.73 M
|
-$107.43 M
|
-$66.39 M
|
-$448.00
|
-$136.74 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.88 |
-1.71 |
-1.43 |
-1.22 |
-1.54 |
0 |
-13.68 |
| EPS Diluted |
-1.88 |
-1.71 |
-1.43 |
-1.22 |
-1.54 |
0 |
-13.67 |
| Weighted Average Shares Out |
$138.10 M
|
$123.08 M
|
$109.68 M
|
$87.76 M
|
$43.20 M
|
$14.38 M
|
$10.00 M
|
| Weighted Average Shares Out Diluted |
$138.10 M
|
$123.08 M
|
$109.68 M
|
$87.76 M
|
$43.20 M
|
$14.38 M
|
$10.00 M
|
| Link |
|
|
|
|
|
|
|
